Akari Therapeutics, Plc (NASDAQ:AKTX) Sees Significant Drop in Short Interest

Akari Therapeutics, Plc (NASDAQ:AKTX) was the target of a large drop in short interest during the month of April. As of April 15th, there was short interest totalling 600 shares, a drop of 94.3% from the March 31st total of 10,500 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily volume of 12,000 shares, the short-interest ratio is currently 0.1 days.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on Akari Therapeutics in a report on Wednesday. They set a “sell” rating on the stock.

Institutional Trading of Akari Therapeutics

A hedge fund recently raised its stake in Akari Therapeutics stock. Omnia Family Wealth LLC boosted its position in shares of Akari Therapeutics, Plc (NASDAQ:AKTX) by 48.2% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 87,628 shares of the biopharmaceutical company’s stock after purchasing an additional 28,511 shares during the quarter. Omnia Family Wealth LLC owned about 1.55% of Akari Therapeutics worth $273,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 5.06% of the company’s stock.

Akari Therapeutics Price Performance

Shares of NASDAQ AKTX opened at $1.19 on Friday. Akari Therapeutics has a 1 year low of $1.08 and a 1 year high of $5.50. The firm has a 50-day simple moving average of $1.79 and a two-hundred day simple moving average of $2.62.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.